Organon & (OGN) Stock: Buy, Sell, or Hold?
OGN - Organon & Co.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 30, 2026 at $13.70 · last confirmed Sep 30, 2026
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
âšī¸ NEUTRAL: OGN is fairly priced but lacks strong directional signals. At 9.8% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.9x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 49/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Protect Your Profits
Holding OGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 18.0% above Wall St target ($11.25)
- BULLISH: Expecting earnings turnaround to 9.8% growth with -2.3% revenue growth
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 3:35 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is OGN showing a specific setup today?
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 48 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 46 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 57 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 48 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
